$ALXN (Alexion Pharmaceuticals, Inc.)

$ALXN {{ '2015-07-06T14:23:44+0000' | timeago}} • Announcement

$ALXN Product Update: Alexion Pharmaceuticals, Inc. announced today that Japan's Ministry of Health, Labour and Welfare approved the Company's New Drug Application for the use of Strensiq® (asfotase alfa), as a treatment for patients in Japan with hypophosphatasia (HPP), a life-threatening, ultra-rare metabolic disorder.

$ALXN {{ '2017-07-27T11:31:03+0000' | timeago}} • Announcement

$ALXN's sale of its flagship drug Soliris was $814MM in 2Q17, compared to $701MM in the prior-year period, representing a 16% increase. Soliris volume increased 18% YoY. Soliris is primarily used to treat a rare disorder that destroys red blood cells.

$ALXN {{ '2017-07-27T11:20:47+0000' | timeago}} • Announcement

$ALXN raised its 2017 forecast for both GAAP and non-GAAP revenue to $3.45-3.525Bil, vs the prior guidance of $3.40-3.50Bil. Non-GAAP EPS projection for this period was also raised to $5.40-5.55, compared to the prior guidance of $5.10-5.30. Meanwhile, the company now sees GAAP EPS in the range of $2.82-3.12.

$ALXN {{ '2017-07-27T11:10:27+0000' | timeago}} • Announcement

Global biopharmaceutical company $ALXN reported 21% jump in revenue in 2Q17 to $912MM. The revenue reflected a benefit of about $35MM due to favorable timing of orders compared to its prior forecast. Net income rose to $165MM, or $0.73 per share, from $120MM, or $0.53 per share, a year ago. On an adjusted basis, $ALXN earned $1.56, up 38% YoY.

$CRL {{ '2017-07-05T12:50:22+0000' | timeago}} • Announcement

$CRL appointed $ALXN EVP Dr Martin Mackay to its BoD.  As a member of the board, he will serve on the Corporate Governance and Nominating Committee and the Science and Technology Committee.

$ALXN {{ '2017-06-23T12:15:29+0000' | timeago}} • Announcement

$ALXN said it received positive opinion from the Committee for Medicinal Products for Human Use to extend the therapeutic indication for Soliris to include the treatment of refractory generalized myasthenia gravis in patients who are ‘anti-acetylcholine receptor antibody-positive’. A final decision from the European Commission is expected in 3Q17.

$ALXN {{ '2017-06-13T21:27:41+0000' | timeago}} • Announcement

$ALXN appointed Paul Clancy as CFO effective July 31, 2017. Clancy will succeed Dave Anderson, who will continue to serve as CFO until July 31, 2017. To ensure a smooth transition, Anderson will then become a Senior Advisor to the CEO and will remain with the company until the end of August.

$ALXN {{ '2017-06-01T20:48:22+0000' | timeago}} • Announcement

$ALXN announced key additions to its executive leadership team effective June 5, 2017. Reporting to CEO Ludwig Hantson will be: John Orloff, M.D., EVP, Head of Research & Development, Anne-Marie Law, EVP, Chief Human Resources Officer, and Indrani Lall Franchini, J.D., EVP, Chief Compliance Officer.

$ALXN {{ '2017-05-23T13:38:35+0000' | timeago}} • Announcement

$ALXN said Martin Mackay, EVP, Head of Research & Development will be retiring at the end of 2017. A search is also underway for a new Head of R&D with SpencerStuart. Clare Carmichael, EVP, Chief Human Resources Officer, will be leaving to pursue new opportunities effective June 1, 2017. Recruiting is underway for a new Head of Human Resources.

$ALXN {{ '2017-05-23T13:37:23+0000' | timeago}} • Announcement

$ALXN appointed Brian Goff as Chief Commercial Officer, effective June 1, 2017. Goff succeeds Carsten Thiel who is leaving to pursue new opportunities effective June 1, 2017. CFO Dave Anderson will resign his position at the end of August. A search for a new CFO is underway with SpencerStuart.

$ALXN {{ '2017-05-16T11:17:52+0000' | timeago}} • Announcement

$ALXN and The Rady Children's Institute for Genomic Medicine have announced a strategic partnership to accelerate the diagnosis of critically-ill newborns with rare genetic disorders. The collaboration combines the institute's genomic research expertise with Alexion data science and bioinformatics capabilities.

$ALXN {{ '2017-04-27T16:48:39+0000' | timeago}} • Webcast

$ALXN continues to face challenge in Latin America and expects that to continue in 2017. The company has faced significant setbacks in its attempts to expand Soliris' label in Latin America. The timing of bulk orders, access challenges in Latin America and the impact of ALXN1210 study recruitment will impact 2Q17 and 3Q17 results, said the company.

$ALXN {{ '2017-04-27T14:21:39+0000' | timeago}} • Infographic

$ALXN Alexion Pharmaceuticals Earnings AlphaGraphics: Q1 2017 highlights

$ALXN {{ '2017-04-27T11:43:38+0000' | timeago}} • Announcement

$ALXN reiterated its FY17 total revenue guidance $3.40-3.50Bil. The company increased its GAAP EPS to $2.80-3.20, from $2.55 to $3.05 and non-GAAP EPS to $5.10-5.30, from $5.00-5.25.

$ALXN {{ '2017-04-27T11:39:42+0000' | timeago}} • Announcement

Drugmaker $ALXN reported 85% growth in its 1Q17 earnings, helped by increased revenues. Net income was $170MM, or $0.75 per share, compared to $92MM, or $0.41MM during 1Q16. Revenues rose 24% YoY to $870MM. Excluding items, $ALXN earned $1.38 per share.

$ALXN {{ '2017-03-27T14:02:17+0000' | timeago}} • Announcement

$ALXN BoD appointed Ludwig Hantson, as CEO and member of the BoD, effective immediately. Hantson succeeds David Brennan, who has led the company as Interim CEO since Dec. 2016. Brennan will remain on the BoD.

$ALXN {{ '2017-03-22T20:24:56+0000' | timeago}} • Announcement

$ALXN submitted an application to Japan's Ministry of Labour and Welfare (MHLW) to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. This is supported by comprehensive Phase 3 REGAIN data.

$ALXN {{ '2017-03-02T21:49:10+0000' | timeago}} • Announcement

$ALXN said Leonard Bell will retire as Chairman of the Board and as a Director at the end of his term, effective as of the Annual Meeting of Shareholders scheduled for May 10, 2017. The Board announced that it expects to appoint David Brennan, Interim CEO and fellow Board member, to succeed Dr. Bell as Chairman.

$ALXN {{ '2017-02-16T15:50:17+0000' | timeago}} • Webcast

$ALXN said that on long term margin expansion, it is going to be positively driven by the long term double digit revenue growth outlook. Also, the company's R&D investment is dependent upon the pipeline opportunities and the ongoing prioritization of investments.

$ALXN {{ '2017-02-16T15:38:20+0000' | timeago}} • Webcast

In Metabolics, $ALXN is guiding revenue of $375-400MM in 2017. The growth for Metabolics is expected to be moderate, mainly in the early part of 2017, due to strong Strensiq performance in 2016, which benefited from patients being identified prior to approval. $ALXN also expects Strensiq revenue per patient to be less than 2016.

$ALXN {{ '2017-02-16T15:35:38+0000' | timeago}} • Webcast

For 2017, $ALXN expects Soliris revenue to be in the $3.025-3.100Bil range and will continue to identify a steady number of new patients with both PNH and aHUS globally. The company also expects the patient recruitment for its ongoing & planned 1210 trials as well as other studies to have a $70-110MM impact headwind on Soliris revenue during 2017.

Recent Transcripts

BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 2:00pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
UTHR (United Therapeutics Corporation)
Thursday, July 27 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, July 26 2017 - 12:30pm
AMGN (Amgen Inc)
Tuesday, July 25 2017 - 9:00pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
OPK (Opko Health, Inc.)
Tuesday, May 9 2017 - 8:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
IMGN (ImmunoGen, Inc.)
Friday, May 5 2017 - 12:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm

AlphaGraphics you may like